CStone’s Anti-CTLA-4 Antibody CS1002 Receives IND Approval in China
SUZHOU, China, Aug. 27, 2018 /PRNewswire/ — CStone Pharmaceuticals (CStone) announced today that its IND application for CS1002, an investigational cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) monoclonal antibody, has been approved by…